Search Videos and More
Podcast
Prostate Cancer Perspectives: Clinical Insights and Emerging Advances
Aside from non-melanoma skin cancers, Prostate cancer, or PCa, is the most common cancer diagnosed for males in the United States and the second leading cause of cancer death for them.
News
Liver Surgery: Minimally Invasive Techniques Can Be an Option
At the majority of cancer centers, patients with liver cancer who are candidates for a major liver resection surgery will be given no options other than traditional open surgery. The experts at Miami Cancer Institute, part of Baptist Health, however, will often perform a minimally invasive approach such as laparoscopic or robotic-assisted surgery when surgery for liver cancer is recommended.
News
Funding for Glioblastoma Research Key to Miami Cancer Institute's Growing Brain Cancer Program
Miami Cancer Institute researchers have received a $3.4 million R01 grant from the National Institutes of Health (NIH) and the National Cancer Institute (NCI) to further glioblastoma research. The award acknowledges the significant contributions of physician-investigators at Baptist Health Miami Cancer Institute.
News
Baptist Health is the Most Awarded Healthcare System in South Florida based on U.S. News & World Report 2024-2025 Rankings
Baptist Health has once again been recognized as one of the best healthcare providers in America and the most award-winning healthcare system in South Florida based on the 2024-2025 U.S. News & World Report rankings. The organization secured a total of 45 High Performing honors.
News
SRS with Immunotherapy Extends Survival in RCC with Brain Metastasis
According to Manmeet Ahluwalia, MD, MBA, FASCO, kidney cancer currently ranks as the fourth most common cancer to metastasize to the brain after lung cancer, breast cancer, and melanoma.
News
Minesh P. Mehta, MD, on NSCLC: Tumor Treating Fields for Brain Metastases
Minesh P. Mehta, MD, of Miami Cancer Institute, part of Baptist Health South Florida, discusses results from the METIS (EF-25) trial evaluating the efficacy and safety of tumor treating fields therapy following stereotactic radiosurgery in patients with mutation-negative non–small cell lung cancer (NSCLC) and brain metastases.
News
Miami Brain Symposium, Seventh Annual
The Miami Brain Symposium will focus on state-of-the-art approaches to the management of primary and metastatic central nervous systems tumors, along with an understanding of current standards of care and a look at future directions.
Podcast
Miami Cancer Institute 2024 ASCO Recap
Join Dr. Michael Zinner, CEO and Executive Medical Director of Baptist Health Miami Cancer Institute, and Dr. Manmeet Ahluwalia, Chief of Medical Oncology, Chief Scientific Officer & Deputy Director, and Fernandez Family Endowed Chair in Cancer Research at Baptist Health Miami Cancer Institute, as they highlight the groundbreaking research
News
Novel Stereotactic Radiosurgery Technology Zaps Brain Tumors
Using a novel stereotactic radiosurgery technology, experts at Miami Neuroscience Institute and Miami Cancer Institute, both part of Baptist Health, now have another option to treat patients with a variety of brain tumors and disorders painlessly and without cutting through the skull
News
Minesh Mehta, M.D., Presenting METIS Trial Results at ASCO
The results of the METIS trial will be discussed by renowned radiation oncologist Minesh Mehta, M.D., at the annual meeting of the American Society of Clinical Oncology (ASCO), May 31-June 4, in Chicago.
News
Miami Cancer Institute Brain Metastases and Glioblastoma Research Coming Out of ASCO
The latest results from a number of brain metastasis clinical trials led by physician-investigators at Miami Cancer Institute, part of Baptist Health, are being presented at the annual meeting of the American Society of Clinical Oncology (ASCO), May 31-June 4, in Chicago.
News
Latest Advances in ADC Therapies for Breast Cancer Highlighted at ASCO
Physician-investigators at Miami Cancer Institute, part of Baptist Health, are preparing to launch a new breast cancer clinical trial that will provide critical information regarding the sequential use of antibody drug conjugates (ADCs) in patients with metastatic breast cancer.